Translations:Anti-obesity medication/18/en
| Medication Name | Trade name(s) | Mechanism of action | Current FDA Status | placebo-adjusted percent bodyweight lost (highest dose studied) |
|---|---|---|---|---|
| Lorcaserin | Belviq | 5-HT2C receptor agonist | Withdrawn for safety reasons | 6.25 percent |
| Sibutramine | Meridia | Serotonin–norepinephrine reuptake inhibitor | Withdrawn due to cardiovascular risks | 19.7 percent |
| Rimonabant | Acomplia, Zimbutli | Cannabinoid receptor antagonist | Withdrawn for safety reasons | 2.6 to 6.3 kilograms (5.7 to 13.9 lb) |
| Fenfluramine | Serotonin releasing agent | Withdrawn for safety reasons | - | |
| Fenfluramine/phentermine (fen-phen) | Pondimin | Withdrawn for safety reasons | 13.9 percent | |
| Dexfenfluramine | Redux | Serotonin releasing agent | Withdrawn for safety reasons | 3.5 kilograms (7.7 lb) |
| 2,4-Dinitrophenol | Uncoupling agent | Withdrawn for safety reasons | 17.1 pounds (7.8 kg) per patient on average (uncontrolled study) |